A rare case of accelerated gingival overgrowth with high dose amlodipine therapy
Keywords:
Hypertension, calcium channel blockers, druginduced gingival hyperplasia, adverse drug reactionAbstract
Introduction: Gingival overgrowth represents an over-exuberant response to a variety of local and systemic conditions. Certain anticonvulsants, immunosuppressive drugs, and a number of calcium channel blockers have been shown to produce similar gingival overgrowth in susceptible patients.
Case report: We report a case of accelerated drug-induced gingival overgrowth in a 60-year-old hypertensive patient taking amlodipine at a dose of 10 mg.
Conclusions: Among the calcium channel blockers, nifedipine is most frequently associated with gingival overgrowth. Whereas, there is limited evidence of amlodipine-induced gingival hyperplasia.
References
Lafzi, A., Farahani, R. M., & Shoja, M. A. (2006). Amlodipine-induced gingival hyperplasia. Medicina oral, patologia oral y cirugia bucal, 11(6), E480–E482.
Nyska, A., Shemesh, M., Tal, H., & Dayan, D. (1994). Gingival hyperplasia induced by calcium channel blockers: mode of action. Medical hypotheses, 43(2), 115–118.
Bhatia, V., Mittal, A., Parida, A. K., Talwar, R., & Kaul, U. (2007). Amlodipine induced gingival hyperplasia: a rare entity. International journal of cardiology, 122(3), e23–e24.
Dougall, H. T., & McLay, J. (1996). A comparative review of the adverse effects of calcium antagonists. Drug safety, 15(2), 91–106.
Ellis, J. S., Seymour, R. A., Thomason, J. M., Monkman, S. C., & Idle, J. R. (1993). Gingival sequestration of amlodipine and amlodipine-induced gingival overgrowth. Lancet (London, England), 341(8852), 1102–1103.
Fares, H., DiNicolantonio, J. J., O'Keefe, J. H., & Lavie, C. J. (2016). Amlodipine in hypertension: a first-line agent with efficacy for improving blood pressure and patient outcomes. Open heart, 3(2), e000473.
Livada, R., & Shiloah, J. (2014). Calcium channel blocker-induced gingival enlargement. Journal of human hypertension, 28(1), 10–14.
Jorgensen M. G. (1997). Prevalence of amlodipine-related gingival hyperplasia. Journal of periodontology, 68(7), 676–678.
Mavrogiannis, M., Ellis, J. S., Thomason, J. M., & Seymour, R. A. (2006). The management of drug-induced gingival overgrowth. Journal of clinical periodontology, 33(6), 434–439.
Naranjo, C. A., Busto, U., Sellers, E. M., Sandor, P., Ruiz, I., Roberts, E. A., Janecek, E., Domecq, C., & Greenblatt, D. J. (1981). A method for estimating the probability of adverse drug reactions. Clinical pharmacology and therapeutics, 30(2), 239–245.
Nery, E. B., Edson, R. G., Lee, K. K., Pruthi, V. K., & Watson, J. (1995). Prevalence of nifedipine-induced gingival hyperplasia. Journal of periodontology, 66(7), 572–578.
Raman, P. G., Mishra, V. N., & Singh, D. (1988). Nifedipine induced gingival hyperplasia. The Journal of the Association of Physicians of India, 36(3), 231–233.
Seymour, R. A., Thomason, J. M., & Ellis, J. S. (1996). The pathogenesis of drug-induced gingival overgrowth. Journal of clinical periodontology, 23(3 Pt 1), 165–175.
Seymour R. A. (1991). Calcium channel blockers and gingival overgrowth. British dental journal, 170(10), 376–379.
Marshall, R. I., & Bartold, P. M. (1999). A clinical review of drug-induced gingival overgrowths. Australian dental journal, 44(4), 219–232.
Triveni, M. G., Rudrakshi, C., & Mehta, D. S. (2009). Amlodipine-induced gingival overgrowth. Journal of Indian Society of Periodontology, 13(3), 160–163.
